EPHA3 as a novel therapeutic target in the hematological malignancies

Expert Review of Hematology

Volumn 5, Issue 3, 2012, Pages 325-340

  Keane, Niamh ^a   Freeman, Ciara ^b   Swords, Ronan ^c   Giles, Francis J ^d  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b QUEEN S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

EphA3; ephrin A5; hematologic malignancy; hematopoietic stem cell; IIIA4; receptor tyrosine kinase; Rho GTPase

Indexed keywords

ADAM10 ENDOPEPTIDASE; EPHRIN A2; EPHRIN A5; EPHRIN RECEPTOR A3; FOCAL ADHESION KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; BINDING AFFINITY; CELL STRUCTURE; DOWN REGULATION; ENZYME ACTIVATION; GENE SILENCING; HEMATOLOGIC MALIGNANCY; HUMAN; INTRACELLULAR SIGNALING; LIGAND BINDING; LYMPHOPROLIFERATIVE DISEASE; MOLECULARLY TARGETED THERAPY; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; STEM CELL; TUMOR MICROENVIRONMENT; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOLOGIC NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTOR, EPHA3;

EID: 84863790430     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.12.19     Document Type: Review

References (101)

1. Unified nomenclature for Eph family receptors and their ligands, the ephrins. Eph Nomenclature Committee. Cell 90(3), 403-404 (1997).
2. Hirai H, Maru Y, Hagiwara K, Nishida J, Takaku F. A novel putative tyrosine kinase receptor encoded by the eph gene. Science 238(4834), 1717-1720 (1987).
3. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 141(7), 1117-1134 (2010).
4. Seiradake E, Harlos K, Sutton G, Aricescu AR, Jones EY. An extracellular steric seeding mechanism for Eph-ephrin signaling platform assembly. Nat. Struct. Mol. Biol. 17(4), 398-402 (2010).
5. Pasquale EB. Eph receptor signalling casts a wide net on cell behaviour. Nat. Rev. Mol. Cell Biol. 6(6), 462-475 (2005).
6. Pasquale EB. Eph-ephrin bidirectional signaling in physiology and disease. Cell 133(1), 38-52 (2008).
7. Lawrenson ID, Wimmer-Kleikamp SH, Lock P et al. Ephrin-A5 induces rounding, blebbing and de-adhesion of EPHA3-expressing 293T and melanoma cells by CrkII and Rho-mediated signalling. J. Cell. Sci. 115(Pt 5), 1059-1072 (2002).
8. Himanen JP, Yermekbayeva L, Janes PW et al. Architecture of Eph receptor clusters. Proc. Natl Acad. Sci. USA 107(24), 10860-10865 (2010).
9. Wimmer-Kleikamp SH, Janes PW, Squire A, Bastiaens PI, Lackmann M. Recruitment of Eph receptors into signaling clusters does not require ephrin contact. J. Cell Biol. 164(5), 661-666 (2004).
10. Stapleton D, Balan I, Pawson T, Sicheri F. The crystal structure of an Eph receptor SAM domain reveals a mechanism for modular dimerization. Nat. Struct. Biol. 6(1), 44-49 (1999).
11. Binns KL, Taylor PP, Sicheri F, Pawson T, Holland SJ. Phosphorylation of tyrosine residues in the kinase domain and juxtamembrane region regulates the biological and catalytic activities of Eph receptors. Mol. Cell. Biol. 20(13), 4791-4805 (2000).
12. Lisabeth EM, Fernandez C, Pasquale EB. Cancer somatic mutations disrupt functions of the EPHA3 receptor tyrosine kinase through multiple mechanisms. Biochemistry 51(7), 1464-1475 (2012).
13. Arvanitis D, Davy A. Eph/ephrin signaling: Networks. Genes Dev. 22(4), 416-429 (2008).
14. Truitt L, Freywald A. Dancing with the dead: EPH receptors and their kinase-null partners. Biochem. Cell Biol. 89(2), 115-129 (2011).
15. Wicks IP, Wilkinson D, Salvaris E, Boyd AW. Molecular cloning of HEK, the gene encoding a receptor tyrosine kinase expressed by human lymphoid tumor cell lines. Proc. Natl Acad. Sci. USA 89(5), 1611-1615 (1992).
16. Smith FM, Vearing C, Lackmann M et al. Dissecting the EPHA3/Ephrin-A5 interactions using a novel functional mutagenesis screen. J. Biol. Chem. 279(10), 9522-9531 (2004).
17. Winslow JW, Moran P, Valverde J et al. Cloning of AL-1, a ligand for an Ephrelated tyrosine kinase receptor involved in axon bundle formation. Neuron 14(5), 973-981 (1995).
18. Day B, To C, Himanen JP et al. Three distinct molecular surfaces in ephrin-A5 are essential for a functional interaction with EPHA3. J. Biol. Chem. 280(28), 26526-26532 (2005).
19. Lackmann M, Oates AC, Dottori M et al. Distinct subdomains of the EPHA3 receptor mediate ligand binding and receptor dimerization. J. Biol. Chem. 273(32), 20228-20237 (1998).
20. Davis TL, Walker JR, Loppnau P, Butler-Cole C, Allali-Hassani A, Dhe-Paganon S. Autoregulation by the juxtamembrane region of the human ephrin receptor tyrosine kinase A3 (EPHA3). Structure 16(6), 873-884 (2008).
21. Vearing C, Lee FT, Wimmer-Kleikamp S et al. Concurrent binding of anti-EPHA3 antibody and ephrin-A5 amplifies EPHA3 signaling and downstream responses: Potential as EPHA3-specific tumortargeting reagents. Cancer Res. 65(15), 6745-6754 (2005).
22. Hu T, Shi G, Larose L, Rivera GM, Mayer BJ, Zhou R. Regulation of process retraction and cell migration by EPHA3 is mediated by the adaptor protein Nck1. Biochemistry 48(27), 6369-6378 (2009).
23. Sahin M, Greer PL, Lin MZ et al. Eph-dependent tyrosine phosphorylation of ephexin1 modulates growth cone collapse. Neuron 46(2), 191-204 (2005).
24. Wegmeyer H, Egea J, Rabe N et al. EphA4-dependent axon guidance is mediated by the RacGAP alpha2-chimaerin. Neuron 55(5), 756-767 (2007).
25. Iwasato T, Katoh H, Nishimaru H et al. Rac-GAP alpha-chimerin regulates motor-circuit formation as a key mediator of EphrinB3/EphA4 forward signaling. Cell 130(4), 742-753 (2007).
26. Miao H, Strebhardt K, Pasquale EB, Shen TL, Guan JL, Wang B. Inhibition of integrin-mediated cell adhesion but not directional cell migration requires catalytic activity of EphB3 receptor tyrosine kinase. Role of Rho family small GTPases. J. Biol. Chem. 280(2), 923-932 (2005).
27. Caron E. Rac signalling: A radical view. Nat. Cell Biol. 5(3), 185-187 (2003).
28. Sahai E, Ishizaki T, Narumiya S, Treisman R. Transformation mediated by RhoA requires activity of ROCK kinases. Curr. Biol. 9(3), 136-145 (1999).
29. Totsukawa G, Yamakita Y, Yamashiro S, Hartshorne DJ, Sasaki Y, Matsumura F. Distinct roles of ROCK (Rho-kinase) and MLCK in spatial regulation of MLC phosphorylation for assembly of stress fibers and focal adhesions in 3T3 fibroblasts. J. Cell Biol. 150(4), 797-806 (2000).
30. Miao H, Burnett E, Kinch M, Simon E, Wang B. Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nat. Cell Biol. 2(2), 62-69 (2000).
31. Smith LM, Walsh PT, Rüdiger T et al. EPHA3 is induced by CD28 and IGF-1 and regulates cell adhesion. Exp. Cell Res. 292(2), 295-303 (2004).
32. Noren NK, Pasquale EB. Eph receptorephrin bidirectional signals that target Ras and Rho proteins. Cell. Signal. 16(6), 655-666 (2004).
33. Miao H, Wang B. EphA receptor signaling - complexity and emerging themes. Semin. Cell Dev. Biol. 23(1), 16-25 (2012).
34. Janes PW, Wimmer-Kleikamp SH, Frangakis AS et al. Cytoplasmic relaxation of active Eph controls ephrin shedding by ADAM10. PLoS Biol. 7(10), e1000215 (2009).
35. Janes PW, Saha N, Barton WA et al. Adam meets Eph: An ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in trans. Cell 123(2), 291-304 (2005).
36. Wimmer-Kleikamp SH, Nievergall E, Gegenbauer K et al. Elevated protein tyrosine phosphatase activity provokes Eph/ephrin-facilitated adhesion of pre-B leukemia cells. Blood 112(3), 721-732 (2008).
37. Nievergall E, Janes PW, Stegmayer C et al. PTP1B regulates Eph receptor function and trafficking. J. Cell Biol. 191(6), 1189-1203 (2010).
38. Nievergall E, Lackmann M, Janes PW. Eph-dependent cell-cell adhesion and segregation in development and cancer. Cell. Mol. Life Sci. 69(11), 1813-1842 (2011).
39. Kilpatrick TJ, Brown A, Lai C, Gassmann M, Goulding M, Lemke G. Expression of the Tyro4/Mek4/Cek4 gene specifically marks a subset of embryonic motor neurons and their muscle targets. Mol. Cell. Neurosci. 7(1), 62-74 (1996).
40. Dottori M, Down M, Hüttmann A, Fitzpatrick DR, Boyd AW. Cloning and characterization of EPHA3 (Hek) gene promoter: Dna methylation regulates expression in hematopoietic tumor cells. Blood 94(7), 2477-2486 (1999).
41. Chiari R, Hames G, Stroobant V et al. Identification of a tumor-specific shared antigen derived from an Eph receptor and presented to CD4 T cells on HLA class II molecules. Cancer Res. 60(17), 4855-4863 (2000).
42. Hafner C, Schmitz G, Meyer S et al. Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin. Chem. 50(3), 490-499 (2004).
43. Feldheim DA, Nakamoto M, Osterfield M et al. Loss-of-function analysis of EphA receptors in retinotectal mapping. J. Neurosci. 24(10), 2542-2550 (2004).
44. Stubbs J, Palmer A, Vidovic M, Marotte LR. Graded expression of EPHA3 in the retina and ephrin-A2 in the superior colliculus during initial development of coarse topography in the wallaby retinocollicular projection. Eur. J. Neurosci. 12(10), 3626-3636 (2000).
45. Brown A, Yates PA, Burrola P et al. Topographic mapping from the retina to the midbrain is controlled by relative but not absolute levels of EphA receptor signaling. Cell 102(1), 77-88 (2000).
46. Jayasena CS, Flood WD, Koblar SA. High EPHA3 expressing ophthalmic trigeminal sensory axons are sensitive to ephrin-A5-Fc: Implications for lobe specific axon guidance. Neuroscience 135(1), 97-109 (2005).
47. Kudo C, Ajioka I, Hirata Y, Nakajima K. Expression profiles of EPHA3 at both the RNA and protein level in the developing mammalian forebrain. J. Comp. Neurol. 487(3), 255-269 (2005).
48. Vaidya A, Pniak A, Lemke G, Brown A. EPHA3 null mutants do not demonstrate motor axon guidance defects. Mol. Cell. Biol. 23(22), 8092-8098 (2003).
49. Nishikimi M, Oishi K, Tabata H, Torii K, Nakajima K. Segregation and pathfinding of callosal axons through EPHA3 signaling. J. Neurosci. 31(45), 16251-16260 (2011).
50. Stephen LJ, Fawkes AL, Verhoeve A, Lemke G, Brown A. A critical role for the EPHA3 receptor tyrosine kinase in heart development. Dev. Biol. 302(1), 66-79 (2007).
51. Frieden LA, Townsend TA, Vaught DB et al. Regulation of heart valve morphogenesis by Eph receptor ligand, ephrin-A1. Dev. Dyn. 239(12), 3226-3234 (2010).
52. Mosch B, Reissenweber B, Neuber C, Pietzsch J. Eph receptors and ephrin ligands: Important players in angiogenesis and tumor angiogenesis. J. Oncol. 2010, 135285 (2010).
53. Dodelet VC, Pasquale EB. Eph receptors and ephrin ligands: Embryogenesis to tumorigenesis. Oncogene 19(49), 5614-5619 (2000).
54. Robillard N, Jego G, Pellat-Deceunynck C et al. CD28, a marker associated with tumoral expansion in multiple myeloma. Clin. Cancer Res. 4(6), 1521-1526 (1998).
55. Pasquale EB. Eph receptors and ephrins in cancer: Bidirectional signalling and beyond. Nat. Rev. Cancer 10(3), 165-180 (2010).
56. Noren NK, Foos G, Hauser CA, Pasquale EB. The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway. Nat. Cell Biol. 8(8), 815-825 (2006).
57. Batlle E, Bacani J, Begthel H et al. EphB receptor activity suppresses colorectal cancer progression. Nature 435(7045), 1126-1130 (2005).
58. Miao H, Li DQ, Mukherjee A et al. EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell 16(1), 9-20 (2009).
59. Singh SK, Clarke ID, Hide T, Dirks PB. Cancer stem cells in nervous system tumors. Oncogene 23(43), 7267-7273 (2004).
60. Brantley-Sieders DM, Jiang A, Sarma K et al. Eph/ephrin profiling in human breast cancer reveals significant associations between expression level and clinical outcome. PLoS ONE 6(9), e24426 (2011).
61. Haldimann M, Custer D, Munarini N et al. Deregulated ephrin-B2 expression in the mammary gland interferes with the development of both the glandular epithelium and vasculature and promotes metastasis formation. Int. J. Oncol. 35(3), 525-536 (2009).
62. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr. Opin. Cell Biol. 17(5), 548-558 (2005).
63. Miao H, Wang B. EphA receptor signaling-Complexity and emerging themes. Semin. Cell. Dev. Biol. 23(1), 16-25 (2012).
64. Miao H, Wei BR, Peehl DM et al. Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat. Cell Biol. 3(5), 527-530 (2001).
65. Ting MJ, Day BW, Spanevello MD, Boyd AW. Activation of ephrin A proteins influences hematopoietic stem cell adhesion and trafficking patterns. Exp. Hematol. 38(11), 1087-1098 (2010).
66. Genander M, Frisén J. Ephrins and Eph receptors in stem cells and cancer. Curr. Opin. Cell Biol. 22(5), 611-616 (2010).
67. Conover JC, Doetsch F, Garcia-Verdugo JM, Gale NW, Yancopoulos GD, Alvarez-Buylla A. Disruption of Eph/ephrin signaling affects migration and proliferation in the adult subventricular zone. Nat. Neurosci. 3(11), 1091-1097 (2000).
68. Nomura T, Göritz C, Catchpole T, Henkemeyer M, Frisén J. EphB signaling controls lineage plasticity of adult neural stem cell niche cells. Cell Stem Cell 7(6), 730-743 (2010).
69. Chumley MJ, Catchpole T, Silvany RE, Kernie SG, Henkemeyer M. EphB receptors regulate stem/progenitor cell proliferation, migration, and polarity during hippocampal neurogenesis. J. Neurosci. 27(49), 13481-13490 (2007).
70. Holmberg J, Genander M, Halford MM et al. EphB receptors coordinate migration and proliferation in the intestinal stem cell niche. Cell 125(6), 1151-1163 (2006).
71. Barker N, Van Es JH, Kuipers J et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449(7165), 1003-1007 (2007).
72. Merlos-Suárez A, Barriga FM, Jung P et al. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 8(5), 511-524 (2011).
73. Batlle E, Henderson JT, Beghtel H et al. Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell 111(2), 251-263 (2002).
74. Nikolova Z, Djonov V, Zuercher G, Andres AC, Ziemiecki A. Cell-type specific and estrogen dependent expression of the receptor tyrosine kinase EphB4 and its ligand ephrin-B2 during mammary gland morphogenesis. J. Cell. Sci. 111(Pt 18), 2741-2751 (1998).
75. Munarini N, Jäger R, Abderhalden S et al. Altered mammary epithelial development, pattern formation and involution in transgenic mice expressing the EphB4 receptor tyrosine kinase. J. Cell. Sci. 115(Pt 1), 25-37 (2002).
76. Kaenel P, Schwab C, Mülchi K, Wotzkow C, Andres AC. Preponderance of cells with stem cell characteristics in metastasising mouse mammary tumours induced by deregulated EphB4 and ephrin-B2 expression. Int. J. Oncol. 38(1), 151-160 (2011).
77. Vermeulen L, De Sousa e Melo F, Richel DJ, Medema JP. The developing cancer stem-cell model: Clinical challenges and opportunities. Lancet Oncol. 13(2), e83-e89 (2012).
78. Huntly BJ, Gilliland DG. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat. Rev. Cancer 5(4), 311-321 (2005).
79. Griffin JD, Löwenberg B. Clonogenic cells in acute myeloblastic leukemia. Blood 68(6), 1185-1195 (1986).
80. Lapidot T, Sirard C, Vormoor J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367(6464), 645-648 (1994).
81. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100(7), 3983-3988 (2003).
82. Galli R, Binda E, Orfanelli U et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 64(19), 7011-7021 (2004).
83. Abdul Khalek FJ, Gallicano GI, Mishra L. Colon cancer stem cells. Gastrointest. Cancer Res. (Suppl. 1), S16-S23 (2010).
84. Jordan CT, Upchurch D, Szilvassy SJ et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14(10), 1777-1784 (2000).
85. Palath V, Vekhande R, Lee A et al. A recombinant human antibody to EPHA3 with pro-apoptotic and enhanced ADCC activity shows selective cytotoxicity against myeloid leukemia cells and CD123-positive leukemic stem cells. ASH Annual Meeting Abstracts 114(22), 1728 (2009).
86. Shapiro VS, Mollenauer MN, Weiss A. Endogenous CD28 expressed on myeloma cells up-regulates interleukin-8 production: Implications for multiple myeloma progression. Blood 98(1), 187-193 (2001).
87. Nair JR, Carlson LM, Koorella C et al. CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment. J. Immunol. 187(3), 1243-1253 (2011).
88. Arruga F, Messa F, Carturan S et al. EPHA3 is abnormally expressed in chronic myeloprolipherative disorders and could represent a new molecular target. AACR Meeting Abstracts 2009(Suppl. 2), 2866 (2009) (Abstract 2866).
89. Cilloni D. EPHA3 kinase is constitutively activated in chronic myeloid leukaemia during progression to accelerated and blast crisis and it could represent a new molecular target. Blood (ASH Annual Meeting Abstracts) 112 (2008). (Abstract 1092)
90. Tibullo D, Barbagallo I, Branca A et al. Mechanisms of heme oxygenase 1-induced resistance to imatinib in CML cells. ASH Annual Meeting Abstracts 116(21), 3385 (2010).
91. Guan M, Liu L, Zhao X et al. Copy number variations of EPHA3 are associated with multiple types of hematologic malignancies. Clin. Lymphoma. Myeloma Leuk. 11(1), 50-53 (2011).
92. Dave B, Mittal V, Tan NM, Chang JC. Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Res. 14(1), 202 (2012).
93. Biddle A, Mackenzie IC. Cancer stem cells and EMT in carcinoma. Cancer Metastasis Rev. 31(1-2), 285-293 (2012).
94. Martin-Rendon E, Hale SJ, Ryan D et al. Transcriptional profiling of human cord blood CD133+ and cultured bone marrow mesenchymal stem cells in response to hypoxia. Stem Cells 25(4), 1003-1012 (2007).
95. Winkler IG, Barbier V, Wadley R, Zannettino AC, Williams S, Lévesque JP. Positioning of bone marrow hematopoietic and stromal cells relative to blood flow in vivo: Serially reconstituting hematopoietic stem cells reside in distinct nonperfused niches. Blood 116(3), 375-385 (2010).
96. Benito J, Shi Y, Szymanska B et al. Pronounced hypoxia in models of murine and human leukemia: High efficacy of hypoxia-activated prodrug PR-104. PLoS ONE 6(8), e23108 (2011).
97. Ashton JM, Balys M, Neering S et al. Oncogene cooperativity analysis reveals a novel set of genes that regulate the in vivo growth and survival of leukemia stem cells. ASH Annual Meeting Abstracts 118(21), 553 (2011).
98. Himanen JP, Chumley MJ, Lackmann M et al. Repelling class discrimination: Ephrin-A5 binds to and activates EphB2 receptor signaling. Nat. Neurosci. 7(5), 501-509 (2004).
99. Boyd AW, Ward LD, Wicks IP et al. Isolation and characterization of a novel receptor-type protein tyrosine kinase (hek) from a human pre-B cell line. J. Biol. Chem. 267(5), 3262-3267 (1992).
100. Hagey A, Lancet JE, Palath V et al. A recombinant antibody to EPHA3 for the treatment of hematologic malignancies: Research update and interim Phase 1 study results. ASH Annual Meeting Abstracts 118(21), 4893 (2011).
101. Palath V, Vekhande R, Baer M et al. A recombinant antibody to EPHA3 with pro-apoptotic and enhanced adcc activity against various hematologic malignancies shows selective inhibition of colony formation from long-term culture-initiating cells (ltc -ics ) in primary leukemia samples. ASH Annual Meeting Abstracts 116(21), 2897 (2010).